TY - JOUR AB - Asthma is one of the diseases that demonstrates a wide range of variation in its clinical expression, in addition to an important heterogeneity in the pathophysiological mechanisms present in each case. The ever‑increasing knowledge of the molecular signalling routes and the development of the Bio Immune(G)ene Medicine [BI(G)MED] therapy in line with this knowledge has revealed a whole novel potential set of self‑regulation biological molecules, that may be used to promote the physiological immunogenic self‑regulation mechanisms and re‑establish the homeostatic balance at a genomic, proteomic and cellular level. The aim of the present study is to demonstrate that the sublingual use of a therapeutic protocol based on BI(G)MED regulatory BIMUREGs in the treatment of chronic asthma may reduce or suppress corticosteroid therapy and avoid its harmful side effects which some patients suffer when using this treatment on a long‑term basis. The clinical efficacy of BI(G)MED for chronic asthma was evaluated through a multi‑centre study carried out in 2016 implementing a 6‑month BI(G)MED treatment protocol for Bronchial Asthma. A total of 61 patients from private medical centres and of European countries including Germany, Austria, France, Belgium and Spain participated. The manuscript describes in detail the clinical efficacy of Bio Immune(G)ene regulatory BI(G)MED treatment protocol that allows the reduction or total removal of the corticosteroid dose in patients with chronic asthma. No adverse reactions were observed. The BI(G)MED regulatory therapy brings novel therapeutic possibilities as an effective and safe treatment of chronic asthma. BI(G)MED was demonstrated to significantly reduce asthma severity when parameter compositions were all analysed by categorical outcomes. Therefore, it is considered a good therapeutic alternative for patients who respond poorly to steroids. AD - European Bio Immune(G)ene Medecine Association, Internal Medicine, 68000 Colmar, France AU - Glady,Gilbert DA - 2018/06/01 DO - 10.3892/etm.2018.6019 EP - 5140 IS - 6 JO - Exp Ther Med KW - asthma respiratory hypersensitivity eosinophils immune system Th1‑Th2 balance microRNAs immunomodulation sublingual immunotherapy lung microbioma PY - 2018 SN - 1792-0981 1792-1015 SP - 5133 ST - Clinical efficacy of implementing Bio Immune(G)ene MEDicine in the treatment of chronic asthma with the objective of reducing or removing effectively corticosteroid therapy: A novel approach and promising results T2 - Experimental and Therapeutic Medicine TI - Clinical efficacy of implementing Bio Immune(G)ene MEDicine in the treatment of chronic asthma with the objective of reducing or removing effectively corticosteroid therapy: A novel approach and promising results UR - https://doi.org/10.3892/etm.2018.6019 VL - 15 ER -